This meeting took place in 2018



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

GPCR Structure and Function: Taking GPCR Drug Development and Discovery to the Next Level (B8)


Organizer(s) Roger K. Sunahara and Christian Felder
February 16—20, 2018
Eldorado Hotel & Spa • Santa Fe, New Mexico USA
Discounted Abstract Deadline: Oct 17, 2017
Abstract Deadline: Nov 15, 2017
Scholarship Deadline: Oct 17, 2017
Discounted Registration Deadline: Dec 18, 2017

Sponsored by Novo Nordisk A/S and Theravance Biopharma

Summary of Meeting:
G protein-coupled receptors (GPCRs) are a critical family of cell surface receptors that detect extracellular stimuli, facilitate intercellular communication and regulate cellular homeostasis. As such, GPCRs remain highly relevant drug discovery targets addressing key unmet medical needs. Recent advances in understanding GPCR signaling networks, coupled with the unraveling of structural details of GPCRs, their signaling partners and in some cases their signaling complexes, have enhanced our understanding of GPCR function. These advances have provided researchers the basic tools to interrogate critical but diverse aspects of GPCR signaling, such as receptor conformation, receptor-effector specificity and the role of receptor subcellular distribution, in signaling efficacy. All of these factors may influence ligand binding and therefore have impact on drug discovery. The availability of atomic-resolution structures of GPCRs alongside the introduction of functional coupling (e.g., biased signaling) is providing the potential for physiologically tailored and therefore disease-specific therapies. However, challenges remain as the design of small molecule tools and potential drugs is both labor-intensive and very costly, requiring large chemical library screening campaigns. In addition, improvements are still needed in GPCR ligand selectivity, signaling specificity and appropriate kinetics to achieve maximal efficacy and reasonable safety. Rational ligand design could significantly reduce both time and cost of drug discovery. Viable approaches are currently being explored through the combination of molecular dynamic simulations, GPCR crystallization and biophysical analysis. Drug efficacy and safety improvements are slow to emerge and can be addressed by the development of physiologically relevant GPCR ligands. Targeting allosteric sites, hetero- and homo-dimers and specific signaling pathways could provide such context- and disease-specific regulation. This conference will highlight the latest developments in GPCR structure/function, ligand discovery and design, intracellular signaling pathways and their impact on modern drug discovery.

View Meeting Program

Scholarships/Awards

Keystone Symposia Future of Science Fund Scholarship Recipients

Antonella Di Pizio
Hebrew University of Jerusalem, Israel

Marie-Lise Jobin
University of W├╝rzburg, Germany

Jeffrey J. Liu
Max Planck Institute of Biochemistry, Germany

Anita K. Nivedha
City of Hope, USA

Jaeho Paek
Harvard Medical School, USA

Ieva Sutkeviciute
University of Pittsburgh, USA